Evidence map›Paper›PMID 35038322›Full record

ReviewAmerican journal of hypertension2022

Excessive Blood Pressure Response to Clonidine in Hospitalized Patients With Asymptomatic Severe Hypertension.

Jonathan Hanna, Lama Ghazi, Yu Yamamoto, Michael Simonov, Tayyab Shah, Francis P Wilson, Aldo J Peixoto

Open access · hybridAbstract readReview
In one paragraph

Review in American journal of hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Transdermal Clonidine for Hypertension: An Underutilized Ally in the Modern Era.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026
    Review
  2. Review
  3. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jonathan HannaDepartment of Internal Medicine, Yale School of Medicine, Yale University, Haven, Connecticut, USA.ORCID 0000-0003-0339-7050
Lama GhaziDepartment of Internal Medicine, Clinical and Translational Research Accelerator, Yale University, New Haven, Connecticut, USA.
Yu YamamotoDepartment of Internal Medicine, Clinical and Translational Research Accelerator, Yale University, New Haven, Connecticut, USA.
Michael SimonovDepartment of Internal Medicine, Clinical and Translational Research Accelerator, Yale University, New Haven, Connecticut, USA.
Tayyab ShahDepartment of Internal Medicine, Yale School of Medicine, Yale University, Haven, Connecticut, USA.
Francis P WilsonDepartment of Internal Medicine, Clinical and Translational Research Accelerator, Yale University, New Haven, Connecticut, USA.
Aldo J PeixotoDepartment of Internal Medicine, Section of Nephrology, Yale School of Medicine, and the Hypertension Program, Yale New Haven Hospital Heart and Vascular Center, New Haven, Connecticut, USA.
Yale University · USYale New Haven Hospital · US

Funding

Renal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI ARONSON, PETER S. · 2008 to 2022
$16.8M
Optimizing Electronic Alerts for Acute Kidney InjuryR01DK113191 · NIDDK · YALE UNIVERSITY · PI WILSON, FRANCIS PERRY · 2018 to 2022
$3.1M
NIDDK NIH HHS P30 DK079310NIDDK NIH HHS R01 DK113191
6 · The paper itself

Abstract

backgroundThere are limited and nonconcordant data on the rapidity and safety of blood pressure response to clonidine in the setting of asymptomatic severe hypertension. We evaluated the blood pressure response to clonidine in hospitalized patients with asymptomatic severe hypertension.

methodsWe performed a review of hospitalized, noncritically ill patients receiving clonidine within 6 hours of developing asymptomatic severe hypertension (systolic blood pressure [SBP] >180 or diastolic blood pressure [DBP] >110 mm Hg in the absence of acute hypertension-mediated target organ damage). The incidence of mean arterial pressure (MAP) reduction by ≥30% at 4 hours after clonidine was the primary endpoint.

resultsWe identified 200 relevant patient encounters (median age 63 years, 48.5% women). Median time to clonidine following asymptomatic severe hypertension was 2.8 hours. A total of 20 (10%) patients had ≥30% MAP reduction within 4 hours after clonidine, and 32 (16%) patients had ≥30% reduction in either SBP, DBP, or MAP. Older age, female sex, and preexisting vascular disease were associated with ≥30% MAP reductions (P < 0.05). Only patient sex and clonidine dose of 0.3 mg were significant in multivariable models. There were 14 adverse events observed within 24 hours of administration of clonidine; most (9) were acute kidney injury. There were no ischemic (myocardial, cerebrovascular) events.

conclusionsA substantial minority of hospitalized patients with asymptomatic severe hypertension experience precipitous blood pressure decline with clonidine, and though blood pressure declines more precipitously in women and those receiving higher doses (0.3 mg specifically), the response to clonidine is generally not predictable on clinical grounds.

Indexed as

ClonidineHypertensionBlood PressureFemaleHumansIncidenceMaleMiddle AgedClonidineasymptomatic severe hypertensionblood pressureclonidinehypertensioninpatient hypertension

Identifiers

PMID35038322
PMCPMC9088839
OpenAlexW4206044782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.